Kenya IVD Classification Rules: Self-Testing, Near-Patient Testing and Class B Downgrades

Content verified as of October 30, 2026

1. Key takeaways

• Kenya applies to in vitro diagnostics a set of classification rules independent of the rules for non-IVD devices (Section 2.15 of the guidelines); the general A/B/C/D device rules are not carried over by analogy.
• Self-testing and near-patient testing fall in principle into Class C; the official examples are blood glucose monitoring, Group B streptococcus near-patient testing, fecal occult blood, and blood gas near-patient testing.
• Downgrading to Class B runs through only two narrow gates: the test result does not determine a medically critical condition, or the test is an initial screen requiring laboratory confirmation. Pregnancy self-testing, fertility testing and urine test strips are the officially listed Class B examples.
• One class apart, the cost gap is material: for imported products the Class B registration fee is USD 200 against USD 1,000 for Class C, and annual retention rises from USD 50 to USD 300.
• Class C also triggers establishment-level requirements: registration of a Class C or Class D establishment requires evidence of premarket approval or registration from at least one IMDRF member regulatory authority, or WHO prequalification confirmation.

2. Legal basis

3. Expert insights

Insight 1: IVD risk comes from how the result is used, not from the device itself

The classification of non-IVD devices anchors on physical dimensions such as contact duration, invasiveness and energy delivery, dimensions that barely function for reagents and analyzers. The real risk of an IVD materializes after the result is issued: an erroneous value translates directly into a dosing decision, a surgical decision or a missed diagnosis. The guidelines therefore build a separate rule set that places the judgment on who interprets the result and what decision the result feeds into. That is also why self-testing and near-patient testing are pushed to Class C by default: with no professional interpretation step in between, the pathway for error propagation is shortest.

Insight 2: Where the two downgrade gates part ways

The guidelines offer two downgrade conditions: the result does not determine a medically critical condition, or the test is an initial screen that requires laboratory confirmation. On the surface this is a judgment about result severity; in substance it also adds a question of whether a re-check mechanism exists. Among self-tests, blood glucose monitoring is Class C while pregnancy self-testing is Class B. The difference lies not in operational difficulty but in whether the result directly triggers critical medical decisions and whether a natural re-visit pathway exists. GRZAN flags a common trap: invoking the generic IFU sentence advising patients to visit a hospital after a positive result as grounds for downgrading. If the testing target of the product is itself the determination of a critical condition, one advisory sentence does not constitute a substantive arrangement of an initial screen with laboratory confirmation.

Insight 3: One class apart, four downstream links change

The registration fee jumps from USD 200 to USD 1,000; annual retention jumps from USD 50 to USD 300; the submission route rises from at least 2 RRA approvals for the same labeled use to at least 3; and establishment registration adds the requirement for an IMDRF member approval or WHO prequalification. These four deltas do not add up linearly; they change the minimum viable project design. A submission that could be launched on two reference approvals must, once in Class C, secure the third approval or switch to the full evaluation route.

Insight 4: Label wording can drag a Class B product back into Class C

Classification rests on intended use, and the external evidence of intended use is the label and the IFU. The same kit labeled for professional use only and labeled as available for personal self-testing present entirely different risk profiles. Under the change notification rules, a modification of the method of use that moves a product from professional to home use is expressly listed as a Review Change requiring prior approval, and a change of intended use is one of the five situations that require submission of a new CSDT. GRZAN’s assessment: once the classification conclusion is settled, every wording choice on the label and IFU becomes evidence maintaining that classification, and marketing claims must pass regulatory review.

4. Practical recommendations

1. Fix the scenario first, then the class. Complete the user, testing location and decision-criticality matrix before applying the Section 2.15 rules.
2. Prepare a downgrade argument package. Any claim to Class B must be supported by a written argument and IFU evidence for either the non-critical-condition condition or the screening-plus-laboratory-confirmation condition.
3. Price the tier jump in parallel. Confirm whether the USD 1,000 registration fee, USD 300 annual retention and the third reference approval are triggered.
4. Lock down label wording. Freeze the label and IFU text before submission and prohibit marketing from adding self-testing or home-use statements unilaterally.
5. Sort the IVD family as a whole. Multiple assays on one platform may fall into different classes; determine each assay before filing as a product family.
6. Prepare IMDRF or WHO evidence early. Class C establishment registration needs it, so start in parallel with product registration.

5. Verification checklist

• □ Has it been confirmed that the independent IVD rules of Section 2.15 apply rather than the general device rules?
• □ Has the scenario assessment been completed on user, location and decision criticality?
• □ For a Class B claim, is there a written argument for at least one of the two downgrade conditions?
• □ Has the fee jump been calculated (USD 200 versus USD 1,000; retention USD 50 versus USD 300)?
• □ Has the number of reference approvals required by the route been confirmed (2 or 3)?
• □ For Class C products, is at least one IMDRF member approval or WHO prequalification file ready?
• □ Are the label and IFU frozen and free of unreviewed self-testing or home-use statements?

Regulatory information verified as of October 30, 2026.

Across African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt, and operates a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, each marked with its verification date. Any figure, timeline or amount that cannot be located in an official source is labeled as a practical estimate and never presented as an assumption.

GRZAN services cover market access strategy and risk classification assessment; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; and regulatory intelligence subscription with corporate compliance record-keeping.

For a Kenya market access plan tailored to your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.